Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis (Q78179343)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

title

Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

author name string

K Parameswaran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

I Purcell

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

M Farrer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

C Holland

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

I K Taylor

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

N P Keaney

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

publication date

1 February 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

volume

93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

page(s)

75-78

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

12 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Long‐term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Aerosolized prostacyclin for preoperative evaluation and post-cardiosurgical treatment of patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Aerosolised prostacyclin in adult respiratory distress syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

Exercise standards. A statement for healthcare professionals from the American Heart Association. Writing Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2899%2990294-9

7 January 2021

10.1016/S0954-6111(99)90294-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10464856%20AND%20SRC:MED&resulttype=core&format=json

12 December 2019

1 reference